165 related articles for article (PubMed ID: 36105325)
1. Biological Effects of Modifications of the Englerin A Glycolate.
Seenadera SPD; Long SA; Akee R; Bermudez G; Parsonage G; Strope J; Peer C; Figg WD; Parker KA; Beech DJ; Beutler JA
ACS Med Chem Lett; 2022 Sep; 13(9):1472-1476. PubMed ID: 36105325
[TBL] [Abstract][Full Text] [Related]
2. Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
Wu Z; Suppo JS; Tumova S; Strope J; Bravo F; Moy M; Weinstein ES; Peer CJ; Figg WD; Chain WJ; Echavarren AM; Beech DJ; Beutler JA
ACS Med Chem Lett; 2020 Sep; 11(9):1711-1716. PubMed ID: 32944138
[TBL] [Abstract][Full Text] [Related]
3. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Carson C; Raman P; Tullai J; Xu L; Henault M; Thomas E; Yeola S; Lao J; McPate M; Verkuyl JM; Marsh G; Sarber J; Amaral A; Bailey S; Lubicka D; Pham H; Miranda N; Ding J; Tang HM; Ju H; Tranter P; Ji N; Krastel P; Jain RK; Schumacher AM; Loureiro JJ; George E; Berellini G; Ross NT; Bushell SM; Erdemli G; Solomon JM
PLoS One; 2015; 10(6):e0127498. PubMed ID: 26098886
[TBL] [Abstract][Full Text] [Related]
4. TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A.
Cheung SY; Henrot M; Al-Saad M; Baumann M; Muller H; Unger A; Rubaiy HN; Mathar I; Dinkel K; Nussbaumer P; Klebl B; Freichel M; Rode B; Trainor S; Clapcote SJ; Christmann M; Waldmann H; Abbas SK; Beech DJ; Vasudev NS
Oncotarget; 2018 Jul; 9(51):29634-29643. PubMed ID: 30038709
[TBL] [Abstract][Full Text] [Related]
5. (-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
Akbulut Y; Gaunt HJ; Muraki K; Ludlow MJ; Amer MS; Bruns A; Vasudev NS; Radtke L; Willot M; Hahn S; Seitz T; Ziegler S; Christmann M; Beech DJ; Waldmann H
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3787-91. PubMed ID: 25707820
[TBL] [Abstract][Full Text] [Related]
6. Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.
Rubaiy HN; Seitz T; Hahn S; Choidas A; Habenberger P; Klebl B; Dinkel K; Nussbaumer P; Waldmann H; Christmann M; Beech DJ
Br J Pharmacol; 2018 Mar; 175(5):830-839. PubMed ID: 29247460
[TBL] [Abstract][Full Text] [Related]
7. Tonantzitlolone is a nanomolar potency activator of transient receptor potential canonical 1/4/5 channels.
Rubaiy HN; Ludlow MJ; Siems K; Norman K; Foster R; Wolf D; Beutler JA; Beech DJ
Br J Pharmacol; 2018 Aug; 175(16):3361-3368. PubMed ID: 29859013
[TBL] [Abstract][Full Text] [Related]
8. Potent, selective, and subunit-dependent activation of TRPC5 channels by a xanthine derivative.
Minard A; Bauer CC; Chuntharpursat-Bon E; Pickles IB; Wright DJ; Ludlow MJ; Burnham MP; Warriner SL; Beech DJ; Muraki K; Bon RS
Br J Pharmacol; 2019 Oct; 176(20):3924-3938. PubMed ID: 31277085
[TBL] [Abstract][Full Text] [Related]
9. An ex vivo perfused ventilated murine lung model suggests lack of acute pulmonary toxicity of the potential novel anticancer agent (-)-englerin A.
Schremmer C; Steinritz D; Gudermann T; Beech DJ; Dietrich A
Arch Toxicol; 2022 Apr; 96(4):1055-1063. PubMed ID: 35165752
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a stable and orally bioavailable englerin analogue.
Fash DM; Peer CJ; Li Z; Talisman IJ; Hayavi S; Sulzmaier FJ; Ramos JW; Sourbier C; Neckers L; Figg WD; Beutler JA; Chain WJ
Bioorg Med Chem Lett; 2016 Jun; 26(11):2641-4. PubMed ID: 27107948
[TBL] [Abstract][Full Text] [Related]
11. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.
Just S; Chenard BL; Ceci A; Strassmaier T; Chong JA; Blair NT; Gallaschun RJ; Del Camino D; Cantin S; D'Amours M; Eickmeier C; Fanger CM; Hecker C; Hessler DP; Hengerer B; Kroker KS; Malekiani S; Mihalek R; McLaughlin J; Rast G; Witek J; Sauer A; Pryce CR; Moran MM
PLoS One; 2018; 13(1):e0191225. PubMed ID: 29385160
[TBL] [Abstract][Full Text] [Related]
12. Importance of a 4-Alkyl Substituent for Activity in the Englerin Series.
Elliott DC; Beutler JA; Parker KA
ACS Med Chem Lett; 2017 Jul; 8(7):746-750. PubMed ID: 28740610
[TBL] [Abstract][Full Text] [Related]
13. (-)-Englerin-A Has Analgesic and Anti-Inflammatory Effects Independent of TRPC4 and 5.
de Sousa Valente J; Alawi KM; Bharde S; Zarban AA; Kodji X; Thapa D; Argunhan F; Barrett B; Nagy I; Brain SD
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203675
[TBL] [Abstract][Full Text] [Related]
14. Englerin a selectively induces necrosis in human renal cancer cells.
Sulzmaier FJ; Li Z; Nakashige ML; Fash DM; Chain WJ; Ramos JW
PLoS One; 2012; 7(10):e48032. PubMed ID: 23144724
[TBL] [Abstract][Full Text] [Related]
15. Englerin A Inhibits T-Type Voltage-Gated Calcium Channels at Low Micromolar Concentrations.
Wardas B; Schneider JG; Klugbauer N; Flockerzi V; Beck A
Mol Pharmacol; 2023 Oct; 104(4):144-153. PubMed ID: 37399325
[TBL] [Abstract][Full Text] [Related]
16. Englerin A-sensing charged residues for transient receptor potential canonical 5 channel activation.
Jeong S; Ko J; Kim M; Park KC; Park EYJ; Kim J; Baik Y; Wie J; Cho AE; Jeon JH; So I
Korean J Physiol Pharmacol; 2019 May; 23(3):191-201. PubMed ID: 31080350
[TBL] [Abstract][Full Text] [Related]
17. Natural and synthetic flavonoid modulation of TRPC5 channels.
Naylor J; Minard A; Gaunt HJ; Amer MS; Wilson LA; Migliore M; Cheung SY; Rubaiy HN; Blythe NM; Musialowski KE; Ludlow MJ; Evans WD; Green BL; Yang H; You Y; Li J; Fishwick CW; Muraki K; Beech DJ; Bon RS
Br J Pharmacol; 2016 Feb; 173(3):562-74. PubMed ID: 26565375
[TBL] [Abstract][Full Text] [Related]
18. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma.
Batova A; Altomare D; Creek KE; Naviaux RK; Wang L; Li K; Green E; Williams R; Naviaux JC; Diccianni M; Yu AL
PLoS One; 2017; 12(3):e0172632. PubMed ID: 28296891
[TBL] [Abstract][Full Text] [Related]
19. Transient Receptor Potential Canonical 4 and 5 Channel Antagonist ML204 Depolarized Pacemaker Potentials of Interstitial Cells of Cajal.
Lee JH; Wu WH; Huang XY; Jun JY; Choi S
J Neurogastroenterol Motil; 2020 Sep; 26(4):521-528. PubMed ID: 32321198
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
Grant CV; Carver CM; Hastings SD; Ramachandran K; Muniswamy M; Risinger AL; Beutler JA; Mooberry SL
Breast Cancer Res Treat; 2019 Sep; 177(2):345-355. PubMed ID: 31230251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
